How can artificial intelligence optimize value-based contracting?

Posted on 22.11.2022 - 10:07
Abstract Efforts in the pharmaceutical market have been aimed at ensuring that the benefits obtained from the introduction of new therapies justify the associated costs. In recent years, drug payment models in healthcare have undergone a dramatic shift from focusing on volume (i.e., size of the target clinical population) to focusing on value (i.e., drug performance in real-world settings). In this context, value-based contracts (VBCs) were designed to align the payment of a drug to its clinical performance outside clinical trials by evaluating the effectiveness using real-word evidence (RWE). Despite their widespread implementation, different factors jeopardize the application of VBCs to most marketed drugs in a near future, including the need for easily measurable and relevant outcomes associated with clinical improvements, and access to a large patient population to assess said outcomes. Here, we argue that the extraction and analysis of massive amounts of RWE captured in patients’ electronic health records (EHRs) will circumvent these issues and optimize negotiations in VBCs. Particularly, the use of Natural Language Processing (NLP) has proven successful in the analysis of structured and unstructured clinical information in EHRs in multicenter research studies. Thus, the application of NLP to analyze patient-centered information in EHRs in the context of innovative contracting can be utterly beneficial as it enables the real-time evaluation of treatment response and financial impact in real-world settings.

CITE THIS COLLECTION

Poveda, Jose Luis; Bretón-Romero, Rosa; Del Rio-Bermudez, Carlos; Taberna, Miren; Medrano, Ignacio H. (2022): How can artificial intelligence optimize value-based contracting?. figshare. Collection. https://doi.org/10.6084/m9.figshare.c.6311209.v1
or
Select your citation style and then place your mouse over the citation text to select it.

SHARE

email
need help?